Unnatural Products closed a $45 million Series B to accelerate its macrocyclic peptide discovery platform and advance lead programs toward the clinic, the company announced. The round was led by The Venture Collective with participation from argenx and Merck Global Health Innovation Fund; proceeds follow a recent licensing pact with Novartis that included significant upfront and potential milestone payments. UNP said its integrated computational and automated-chemistry platform enables design of cell‑permeable macrocycles and could unlock targets historically undruggable by biologics or small molecules.